IP Library Granted Patent US 11,260,056
Granted Patent B2
US 11,260,056 · App. 15/764,174 · Granted Mar 1, 2022

Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for use in the treatment of cough

Inventors: Anthony P. Ford (Palo Alto, CA); Kathleen Sereda Glaub (San Leandro, CA); Michael M. Kitt (Mountain View, CA); Steven Smith (San Jose, CA)
Assignee: AFFERENT PHARMACEUTICALS, INC.
A61K31/505A61K9/0014A61K9/0053A61K9/0078A61K9/06A61K9/10A61K9/2054A61K9/4858A61K45/06A61K47/38A61K47/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,260,056
App. No.
15/764,174
Granted
Mar 1, 2022
Kind
B2
Abstract

Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are as defined herein.

Claims (18)

1. A method for treating chronic cough, comprising administering to a patient with chronic cough from about 30 mg to about 50 mg twice daily of a compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is hydrogen or C 1 -C 6 alkyl; and

R 2 is: alkyl; aminosulfonyl; halo; amido; haloalkyl; alkoxy; hydroxy; haloalkoxy; nitro; hydroxyalkyl; alkoxyalkyl; hydroxyalkoxy; alkynylalkoxy; alkylsulfonyl; arylsulfonyl; carboxyalkyl; cyano or alkylcarbonyl; and

wherein the method exhibits a reduced taste disturbance relative to a taste disturbance resulting from administering a dose of about 100 mg or greater of the compound of formula (I), or the pharmaceutically acceptable salt thereof, twice daily to a patient with chronic cough.

2. The method of claim 1 , wherein the chronic cough is idiopathic or treatment resistant cough.

3. The method of claim 1 , wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is administered twice daily for days, weeks, months or years.

4. The method of claim 1 , wherein the chronic cough is refractory chronic cough.

5. The method of claim 1 , wherein the reduced taste disturbance is relative to a taste disturbance resulting from administering about 100 mg of the compound of Formula (I), or the pharmaceutically acceptable salt thereof, twice daily to a patient with chronic cough.

6. The method of claim 1 , wherein the chronic cough is daytime cough.

7. The method of claim 1 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

9. A method for treating chronic cough, comprising administering to a patient with chronic cough from about 30 mg to about 50 mg twice daily of a pharmaceutically acceptable salt of the following compound:

wherein the method exhibits a reduced taste disturbance relative to a taste disturbance resulting from administering a dose of about 100 mg or greater of the pharmaceutically acceptable salt of the compound of formula (I) twice daily to a patient with chronic cough.

10. The method of claim 9 , wherein the reduced taste disturbance is relative to a taste disturbance resulting from administering about 100 mg of the pharmaceutically acceptable salt of the compound of formula (I) twice daily to a patient with chronic cough.

11. The method of claim 9 , wherein the reduced taste disturbance is relative to a taste disturbance resulting from administering about 600 mg of the pharmaceutically acceptable salt of the compound of formula (I) twice daily to a patient with chronic cough.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER 17197705 PREVIOUSLY RECORDED AT REEL: 061574 FRAME: 0579. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Dec 1, 2022
From: AFFERENT PHARMACEUTICALS, INC.
To: AFFERENT PHARMACEUTICALS, INC.
Reel/Frame 062036/0001 →
CHANGE OF ADDRESS Recorded Sep 30, 2022
From: AFFERENT PHARMACEUTICALS, INC.
To: AFFERENT PHARMACEUTICALS, INC.
Reel/Frame 061574/0579 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2018
From: FORD, ANTHONY P.; GLAUB, KATHLEEN SEREDA; KITT, MICHAEL M.; SMITH, STEVEN
To: AFFERENT PHARMACEUTICALS, INC.
Reel/Frame 045377/0480 →
Continuity (3)
Provisional Application 62336381 · May 13, 2016
Provisional Application 62234584 · Sep 29, 2015
Related Publication 20180280388A1 · Oct 4, 2018